SCHEMBL206172

SCHEMBL206172

CN(C)C1(Cc2cccc(Cl)c2)CCC(NC(=O)CCC(=O)NCCc2ccccn2)CC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 2/20 0.42
PKM P14618 2/20 0.42
SIGMAR1 Q99720 2/20 0.42
HTT P42858 1/20 0.42
F2 P00734 1/20 0.42
FPR3 P25089 1/20 0.42
NPC1 O15118 2/20 0.41
LMNA P02545 2/20 0.41
EPHX2 P34913 1/20 0.40
THRB P10828 1/20 0.40
HPGD P15428 1/20 0.40
SLC12A2 P55011 1/20 0.39
SLC12A5 Q9H2X9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208282 0.92 HTT (0.46) KMT2AMEN1SMN1; SMN2RAB9ASIGMAR1
SCHEMBL208454 0.89 ALDH1A1 (0.53) KMT2AMEN1ALDH1A1SMN1; SMN2RAB9A
SCHEMBL205735 0.89 ALDH1A1 (0.55) KMT2AMEN1ALDH1A1SMN1; SMN2RAB9A
SCHEMBL206988 0.86 ALDH1A1 (0.51) KMT2AMEN1ALDH1A1SMN1; SMN2RAB9A
SCHEMBL208794 0.85 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1SMN1; SMN2RAB9A
SCHEMBL207910 0.85 OPRM1 (0.50) KMT2AMEN1ALDH1A1SMN1; SMN2SIGMAR1
Hydrochloric Acid SCHEMBL206061 0.85 ALDH1A1 (0.50) KMT2AMEN1ALDH1A1SMN1; SMN2RAB9A
SCHEMBL206288 0.84 ALDH1A1 (0.50) KMT2AMEN1ALDH1A1SMN1; SMN2RAB9A
SCHEMBL207325 0.84 NPC1 (0.49) KMT2AMEN1ALDH1A1SMN1; SMN2RAB9A
SCHEMBL208016 0.84 HPGD (0.48) KMT2AALDH1A1SMN1; SMN2SIGMAR1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP disclosed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD KMT2A 3604/4885MEN1 713/4885ALDH1A1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.